Quotes 5-day view Delayed Nasdaq
02/19/2021
02/22/2021
02/23/2021
02/24/2021
02/25/2021
Date
64.37(c)
64.11(c)
63.68(c)
63.71(c)
62.79 Last
6 054 624
6 597 733
8 714 604
6 533 104
7 678 172 Volume
-1.32% -0.40% -0.67% +0.05% -1.44% Change
Sales 2020
24 482 M - -
Net income 2020
137 M - -
Net Debt 2020
24 797 M - -
P/E ratio 2020
534x
Yield 2020
4,25%
Sales 2021
24 857 M - -
Net income 2021
7 236 M - -
Net Debt 2021
17 538 M - -
P/E ratio 2021
11,8x
Yield 2021
4,43%
Capitalization
78 709 M 78 709 M -
EV / Sales 2020
4,23x
EV / Sales 2021
3,87x
Nbr of Employees
11 800
Free-Float
99,9%
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.5%): especially royalties and...
Notations Surperformance© of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
All news about GILEAD SCIENCES, INC.
News in other languages on GILEAD SCIENCES, INC.
Analyst Recommendations on GILEAD SCIENCES, INC.
Gilead Sciences : raises 2020 profit forecast on remdesivir strength
Chart GILEAD SCIENCES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends GILEAD SCIENCES, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
32
Average target price
74,00 $
Last Close Price
63,71 $
Spread / Highest target
57,0%
Spread / Average Target
16,2%
Spread / Lowest Target
-7,39%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
